Neoplasms Clinical Trial
Official title:
A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma
The primary end-point of the study is to determine the specificity and sensitivity of OTL38 in identifying pituitary adenomas when excited by an imaging probe. The investigators intend to enroll 50 patients in this study. The study is focusing on patients presenting with suspected pituitary adenomas who are considered to be good surgical candidates.
Pituitary adenomas have an estimated prevalence in the population of approximately 10%, and
although they are predominantly benign tumors, they can cause significant disability from
mass effect (visual field deficits and cranial nerve deficits) and from hypersecretory
syndromes (Cushing's disease, acromegaly, hyperprolactinemia). Approximately 30% of all
pituitary adenomas are nonfunctioning or endocrinologically silent, and despite the lack of
hormonal overexpression they represent the great majority of patients of who undergo surgery
given the threat of apoplexy and compression of adjacent neural structures. Surgical
resection via transsphenoidal surgery remains the primary treatment modality for almost all
pituitary adenomas except prolactinomas. Residual tumor, however, is quite common after
surgical resection and is seen in up to 20% of surgical cases. By ensuring a negative margin
through imaging during surgery, it would be possible to minimize the need for postoperative
radiation therapy and/or radiosurgery and subsequent surgery as well.
Gross total resection (GTR) of a pituitary adenoma is theoretically simple but practically
difficult given the intimate association of the pituitary gland with critical neurovascular
structures including the internal carotid artery, optic nerves, cavernous sinus contents and
adjacent frontal lobe and third ventricle. In a recent meta-analysis, functioning pituitary
adenoma (Cushing's disease, prolactinoma, acromegaly) was demonstrated to have a gross total
resection rate of only 78% (n=664). In another review, tabulated through multiple studies,
demonstrated that for nonfunctioning pituitary adenoma, gross total resection rate ranged
from 66 to 93% (n=778). Moreover, a comparison of endoscopic and microscopic removal of
pituitary adenoma found the gross total resection rate was 66% using endoscopic pituitary
techniques. In this context of limited ability to achieve GTR, intraoperative MRI was
introduced for assessment of the degree of resection for pituitary adenoma. The
intraoperative MRI is expensive, cumbersome, and impractical. A simpler means of determining
the degree of resection is greatly needed in the field of brain surgery, and specifically
pituitary surgery.
Pituitary adenomas are the ideal disease to investigate intra-operative imaging. Multiple
studies have demonstrated that nonfunctioning pituitary adenomas express folate receptor
alpha (FRα), therefore making folate receptors (FR) the ideal targets for imaging agents.
While folate will initially distribute to all cells, redistribution, metabolism, and
excretion will eliminate most of this agent from healthy tissues within 2-3 hours. Tumor
cells that over express FRα will retain folate and any fluorescent labeled folate conjugate
(such as OTL38) and internalize this.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |